AlphaStocks
6.0
Consider Buy

Arrowhead Pharmaceuticals, Inc. (ARWR)

As of Sep 20, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) scores 6.0/10 on AlphaStocks' five-model composite, #50 of 168 Health Care stocks.

Health Care / Biotechnology

S&P MidCap 400

$66.56

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 4 of 5 models — moderate confidence

Data as of Sep 20, 2026

#50out of 168 in Health Care

Is ARROWHEAD PHARMACEUTICALS, INC. a Good Investment in 2026?

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) scores 6.0 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates ARROWHEAD PHARMACEUTICALS, INC. as Attractive (5/9). However, the Greenblatt Magic Formula model rates it Caution — Earnings yield 1.0% · ROC 9%. ARROWHEAD PHARMACEUTICALS, INC. ranks #50 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

ROE-0.3Market Cap9B

Valuation

Currently unprofitable — fair value estimate not available.

Fair value estimate not available for this stock.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Neutral

Business quality & competitive moat

Graham

Neutral

Price vs intrinsic value

Lynch

Limited Data

Growth rate vs price (PEG)

Greenblatt

Caution

Earnings yield 1.0% · ROC 9%

Frequently Asked Questions

Is ARROWHEAD PHARMACEUTICALS, INC. (ARWR) a good investment?
As of Sep 20, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) scores 6.0/10 on AlphaStocks' five-model composite, #50 of 168 Health Care stocks. That is a middle-of-the-pack score with no strong signal either way. Currently unprofitable — fair value estimate not available.
What is ARROWHEAD PHARMACEUTICALS, INC.'s Piotroski F-Score?
ARROWHEAD PHARMACEUTICALS, INC.'s Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is ARWR overvalued or undervalued?
A precise fair value estimate is not available for ARWR. Currently unprofitable — fair value estimate not available.
How does ARWR compare to other Health Care stocks?
ARROWHEAD PHARMACEUTICALS, INC. ranks #50 out of 168 stocks in the Health Care sector, placing it in the top 30% of its sector by composite score. This is an above-average position relative to sector peers.
What do investment models say about ARWR?
AlphaStocks evaluates ARWR using five proven investment models. Piotroski: Attractive; Buffett: Neutral; Graham: Neutral; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 6.0/10.

Similar Stocks

ABBVINCYHRMY

Compare ARWR with

ABBV vs ARWRARWR vs INCYARWR vs HRMYARWR vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer